Scholars Central

PerspectivePublished 21 Jul 2016

Human papillomavirus screening and vaccines for cancer prevention: what is on the horizon?

Authors: Cornelia L Trimble, Patti Gravitt, Richard BS Roden

Clinical Practice

Volume 5 · Issue 3 · Pages 295

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

This perspective aims to look at how the recently licensed human papillomavirus (HPV) vaccines, based on L1 virus-like particles (VLPs), will impact cervical cancer globally, and what remains to be done in this field. The current VLP vaccines protect against infection from a substantial proportion, but not all, of the oncogenic HPV genotypes, and they have no proven therapeutic benefit for patients with HPV disease. Furthermore, they are too costly for sustained global use, and it is unclear how they may impact current cytologic screening protocols. A number of new technologies show promise in addressing these issues, including molecular screening tools and alternative vaccine strategies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Cornelia L Trimble”
  • BylineArticles whose byline prints “Patti Gravitt”
  • BylineArticles whose byline prints “Richard BS Roden”